Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06312020 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome
A Phase 2 study of Sjogren's Syndrome, sponsored by Amgen.
- Active
- Registry status
- Phase 2
- Development phase
- 209
- Enrollment target
- 20
- Study locations
NCT06312020 is a Phase 2 study of Sjogren's Syndrome that is active but no longer recruiting, run by Amgen. The registered enrollment target is 209 participants, below the 278-participant average among 20 other Sjogren's Syndrome trials with a reported enrollment target (25% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT06312020, a Phase 2 study of Sjogren's Syndrome, is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 209 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to measure the efficacy and safety of HZN-1116 in participants with Sjogren's syndrome (SS).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG HZN-1116
Study Locations (20)
Florida
- Life Arc Research Centers Corp - Miami
- IRIS Research and Development LLC - Plantation
- Clinical Research of West Florida Inc - Tampa - Tampa
Texas
- Tekton Research, LLC - W Gate Blvd - Austin - PPDS - Austin
- Prolato Clinical Research Center - Houston
- R & H Clinical Research-777 S Fry Rd - Katy
Ciudad Autónoma de BuenosAires
- DOM Centro de Reumatología - Buenos Aires
- Expertia S.A- Mautalén Salud e Investigación - Buenos Aires
- Centro Privado de Medicina Familiar - Buenos Aires
Arizona
- Arizona Arthritis & Rheumatology Research-S Vineyard Ave - Mesa
- Arizona Arthritis and Rheumatology Associates -4550 E Bell Rd - Phoenix
California
- Neurovations Research - Napa
Georgia
- Augusta University Medical Center-Augusta-1120 15th St - Augusta
Massachusetts
- Tufts Medical Center - 800 Washington St - PPDS - Boston
New York
- Pioneer Clinical Research NY - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 209 participants |
| Start Date | 2024-05-09 |
| Est. Completion | 2026-11-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06312020
The ClinicalTrials.gov registry entry for NCT06312020 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 209 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 278-participant average among 20 other Sjogren's Syndrome trials with a reported enrollment target (25% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sjogren's Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06312020 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, Texas, Ciudad Autónoma de BuenosAires.
Frequently Asked Questions
What is clinical trial NCT06312020 about?
NCT06312020 is a clinical study titled "A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome". The purpose of this study is to measure the efficacy and safety of HZN-1116 in participants with Sjogren's syndrome (SS).
What is the current status of trial NCT06312020?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 209 participants. The study started on 2024-05-09. Estimated completion is 2026-11-24.
What conditions does trial NCT06312020 study?
This clinical trial studies the following conditions: Sjogren's Syndrome.
What interventions are being tested in trial NCT06312020?
The interventions under investigation include: Placebo (DRUG), HZN-1116 (DRUG).
Who is sponsoring clinical trial NCT06312020?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06312020 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sjogren's Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease
RECRUITING · Phase 2
-
Etanercept Therapy for Sjogren's Syndrome
COMPLETED · Phase 2
-
A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome
COMPLETED · Phase 2
-
Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops
COMPLETED · Phase 2
-
Rheumatology Diet Study
RECRUITING
-
Creating Health Course Study for People With Rheumatological Conditions
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.